Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OMP Ranked in Highest Two Across All Four Use Cases in the 2026 Gartner(R) Critical Capabilities for Supply Chain Planning Solutions: Process Industries30.4.2026 15:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / April 30, 2026 / OMP, a leading provider of AI-powered supply chain planning, has been ranked in highest two across all four Use Cases in the 2026 Gartner® Critical Capabilities for Supply Chain Planning Solutions report for process industries. This report, a companion to the Gartner® Magic Quadrant™, evaluates 16 vendors on Critical Capabilities and real-world Use Cases, helping organizations assess how well solutions support different levels of supply chain planning maturity. This recognition follows OMP's recent position as highest in Ability to Execute and furthest in Completeness of Vision in the 2026 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions: Process Industries. Get the full Gartner® Critical Capabilities report. Consistent strength in real-world planning Use Cases The critical capabilities that most distinguish supply chain planning (SCP) vendors for process industries from each other in 2026 are AI-driven planning and decisio
Karbon-X Advances Sur del Meta REDD+ Project with Biodiversity Partnership30.4.2026 15:00:00 CEST | Press release
Collaboration supports the use of ecological data in project design as demand for high-integrity carbon credits accelerates. CALGARY, AB / ACCESS Newswire / April 30, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today announced the formalization of a strategic partnership with Fundación BioHerencia, a participating landowner of the REDD+ project Sur del Meta currently being implemented in Colombia. The partnership aims to embed biodiversity conservation within the REDD+ project by combining the landowner's conservation expertise with community-based monitoring efforts. The agreement establishes a technical, scientific, and operational framework to support the integration of field-based ecological data into the project's Measurement, Reporting, and Verification (MRV) systems. As a participating landowner within the REDD+ project, BioHerencia owns Harpy Eagle
Datavault AI and Kings Mine Capital Agree to Establish $150 Million+ GoldVault(TM) Tokenization Program30.4.2026 15:00:00 CEST | Press release
Agreement Contemplates Bullion at $3,000 an Ounce to Spot for 24-Month Delivery with $40 Million Projected Profit at $5000 an Ounce. GoldVault™ Tokens Issue at Discount to Spot with Production-Linked Royalty Stream PHILADELPHIA, PA / ACCESS Newswire / April 30, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, and King Mining Capital ("King Mining Capital") today announced that they have entered into a agreement for a multi-component strategic transaction that will combine a Datavault AI equity investment in King Mining Capital, a Datavault AI stock-funded purchase of 20,000 ounces of physical gold bullion, and the launch of a $150 million-plus GoldVault™ tokenization program backed by King Mining Capital's high-grade gold resources. Direct Equity, Physical Bullion, and Stock-Funded Consideration Subject to entering into a definitive agreem
doola Launches Agentic LLC Formation: Start a U.S. Company in Minutes Without Leaving Claude or Replit30.4.2026 14:00:00 CEST | Press release
Start a U.S. Company in Minutes Without Leaving Claude or Replit Founders can go from idea to LLC without ever leaving the tool they're building in doola is the first business formation platform to launch a Model Context Protocol (MCP) integration for LLC formation, enabling founders to start an LLC through a conversation directly in Claude or Replit. The flow takes minutes. No new browser. No context switching. Available to US and non-US founders and developers (no US SSN required). doola has helped more than 15,000 founders in 175+ countries start and scale US businesses, backed by $13M in venture capital from Y Combinator, HubSpot Ventures, Nexus Venture Partners, and other top investors. NEW YORK CITY, NY / ACCESS Newswire / April 30, 2026 / doola, the AI Business-in-a-Box™ for global entrepreneurs, today became the first business formation platform to enable native LLC formation within AI agents. With new MCP integrations for Claude and Replit, founders can now form a Wyoming LLC
GoodData is Now GoodData.AI, Reflecting Its AI-First Direction30.4.2026 11:00:00 CEST | Press release
The brand update marks the company's continued shift toward intelligence-driven analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 30, 2026 / GoodData, the AI-native decision intelligence platform, today announced it is rebranding as GoodData.AI. The rebrand reflects a strategic direction GoodData has been building toward for several years. The platform has been developed around a core conviction: that governed, AI-native analytics is the foundation every serious enterprise needs. The semantic layer, context management, open architecture, composability, agentic frameworks, and analytics-as-code introduced over that period were each a step toward that foundation. "GoodData.AI is the name that reflects both where we've been and where the market is going," said Roman Stanek, CEO and Founder of GoodData.AI. "Enterprises need analytics that AI can operate, govern, and trust at scale. That's what we're built for, and we're moving faster than ever to get customers there." That pace is vis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom